# BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

> **NCT03482635** · PHASE2,PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 98 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Spesolimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03482635
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-27
- **Primary completion:** 2020-05-18
- **Final completion:** 2020-05-18
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03482635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03482635, "BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03482635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*